Built on diversity
As GAP’s first-ever blood and digital biomarker platform study, Bio-Hermes enrolled more than 1,000 study volunteers:
- 24% percent from traditionally underrepresented communities — vastly surpassing the diversity rate of other clinical trials
- 400+ healthy, or without expressed problems with their memory or thinking
- 300+ with mild cognitive impairment
- 270+ with mild Alzheimer’s disease
Built on meaningful data
By providing head-to-head comparisons of data available from many leading Alzheimer’s diagnostic tests today, Bio-Hermes reduces historical barriers to access to timely diagnosis and care.
- 14 blood-based biomarkers: peripheral biomarkers
- 15 digital tests: speech analytics, computerized cognitive assessment using adaptive psychophysics, and digital remote brain health screenings
- 4 cognitive: retinal imaging, PET Central Reader, statistical analysis, and artificial intelligence
Built on collaboration
Part of Bio-Hermes’ success is in the impressive collaboration that brought together leading biopharma, technology and nonprofit partners and seventeen GAP-Net clinical research sites around the United States.
What comes next
The success of the Bio-Hermes study opens up the door for new research and diagnostics. This is especially true when data from Bio-Hermes becomes available to Alzheimer’s researchers worldwide as part of the Alzheimer’s Disease Discovery Initiative’s AD Workbench.
The study’s success in improving participation of participants who are traditionally underrepresented in clinical trials paves the way for future clinical research to represent the people who are most likely to develop Alzheimer’s and other neurodegenerative diseases.
Thank you to our research & scientific partners
- Alzheimer’s Drug Discovery Foundation (ADDF)
- Aural Analytics
- Gates Ventures
- GNS Healthcare
- University of Gothenburg